Evolent Health and Centene Agree to Expanded Partnership for Oncology Specialty Care for Medicare Advantage Members

Evolent Health (NYSE: EVH) announced on March 29, 2023, an agreement with Centene Corporation (NYSE: CNC) to enhance its Technology and Services solution for oncology care.

Rhea-AI Summary

Evolent Health (NYSE: EVH) announced on March 29, 2023, an agreement with Centene Corporation (NYSE: CNC) to enhance its Technology and Services solution for oncology care. This partnership will extend Evolent's oncology services to Centene’s Medicare Advantage members across the nation, deepening their existing collaboration in the specialty care market. Both companies aim to optimize oncology outcomes while managing costs effectively. Evolent's established platform, backed by scientific advisory boards, focuses on clinical quality and financial accountability, ensuring improved care delivery for patients.

Positive

• Expansion of oncology services for Centene's Medicare Advantage members enhances Evolent's market presence.
• Strengthening the partnership with Centene indicates confidence in Evolent's value-based care model.
• Evolent's established platform promotes clinical quality and financial accountability, potentially improving patient outcomes.

Negative

• None.

Argus Session date unavailable

+3.46% session move Open Argus

Details

News Market Reaction – EVH

The recorded move for EVH in the trading session of this news was +3.46%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WASHINGTON, March 29, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven value-based specialty care solutions to payers and providers, today announced an agreement to expand its Technology and Services solution for oncology with its existing partner, Centene Corporation, (NYSE: CNC). 

Centene will expand its use of Evolent Health's oncology solution across its Centene and WellCare Medicare Advantage (MA) members nationally. This agreement deepens the specialty care partnership between Centene and Evolent in the MA market.

Ken Fasola, President of Centene Corporation said, "We continue to be impressed with Evolent's value-based specialty care platform and are excited about the announcement today to expand their oncology services into our Medicare Advantage markets later this year. More broadly, we look forward to continuing to expand our strategic partnership in the years to come."

"We are excited to expand our partnership with Centene to enable their goal of providing the most valuable tools to manage the quality and cost of oncology care for Medicare Advantage members nationally," stated Dan McCarthy, President of Evolent Health. We are proud to align closely with Centene with the collective goal of optimizing oncology outcomes for all plan members, their family and caregivers."

For over twenty years through its Technology & Services offering, Evolent has provided a leading platform to payers that helps drive clinical quality and financial accountability for total oncology spending. Evolent's Precision Pathways^℠ incorporate the latest science and innovative new therapies as determined by an independent scientific advisory board of leading academic and community oncologists. Evolent's clinical depth and physician empowerment model create an ecosystem of trust and support around oncologists, resulting in sustained improvements in quality and cost.

About Evolent Health
Evolent Health delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance's Population Health Program Accreditation and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.

Contacts:
Seth R. Frank
Vice President, Investor Relations
Evolent Health, Inc.
sfrank@evolenthealth.com
571-895-3919 (W)

View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-health-and-centene-agree-to-expanded-partnership-for-oncology-specialty-care-for-medicare-advantage-members-301785149.html

SOURCE Evolent Health

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the recent partnership between Evolent Health and Centene Corporation?

Evolent Health announced an expanded partnership with Centene Corporation to enhance oncology specialty care services for Centene's Medicare Advantage members across the U.S.

How will the partnership between EVH and CNC impact Medicare Advantage members?

The partnership will provide improved oncology care solutions aimed at optimizing patient outcomes and managing care costs for Medicare Advantage members.

When was the partnership agreement between Evolent Health and Centene announced?

The partnership agreement was announced on March 29, 2023.

What are the key benefits of Evolent's oncology solution for Centene?

Evolent's oncology solution focuses on clinical quality and financial accountability, which helps to manage the quality and cost of oncology care.

How does Evolent Health's platform support oncologists?

Evolent's platform empowers oncologists by providing an ecosystem of trust and support, which leads to sustained improvements in both the quality of care and cost management.